Medicare’s second round of drug-price negotiations produced its headline number, and it belongs to the diabetes drug seniors ask about most. Beginning in 2027, the negotiated Medicare price for a monthly supply of Ozempic falls to $274, down from a $959 list price, a cut of about 71 percent. The figure is the maximum fair price that federal negotiators and Novo Nordisk agreed to under the Inflation Reduction Act, and it applies to the price Medicare and its drug plans pay. What an individual owes at the counter still depends on the plan, but the number underneath every calculation just dropped by nearly $700.
How the $274 price was set
The price is the product of the Medicare Drug Price Negotiation Program, the mechanism created by the Inflation Reduction Act that lets the federal government bargain directly with manufacturers on a limited set of high-spending drugs. Ozempic reached the list because its active ingredient, semaglutide, accounts for enormous Medicare spending. The same negotiated ceiling of $274 a month covers the semaglutide family, including Rybelsus and lower-dose Wegovy, while higher doses of Wegovy land at a separate $385 figure.
According to the negotiated prices CMS published, the $274 amount is a maximum fair price rather than a copay. It sets what Medicare recognizes as the drug’s cost, which then flows into how a Part D plan calculates deductibles, coinsurance, and the share a beneficiary pays. A plan can still structure cost sharing in different ways, but it must build on a base that is dramatically lower than the list price that governed Ozempic before negotiation.
The 2027 prices are the program’s second cycle, not its debut. A first round of negotiations set lower prices on ten high-spending drugs that took effect at the start of 2026, and the semaglutide products join a group of fifteen additional medicines in the round that begins in 2027. The Inflation Reduction Act directs the agency to keep adding drugs each year thereafter, so the roster of medicines carrying a capped Medicare price is built to lengthen rather than reset.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. The free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
What a diabetes patient actually saves
The distance between $959 and $274 is where the real story sits for a retiree managing type 2 diabetes on a fixed income. Before negotiation, a semaglutide prescription could push a beneficiary quickly through a plan’s cost-sharing phases, and the underlying price drove every dollar of that math. A lower recognized price means the drug consumes less of the deductible and less of the coinsurance tier, and it interacts with the redesigned Part D benefit that now caps annual out-of-pocket drug spending.
The negotiated price also lands inside a Part D benefit that has already been rebuilt around a hard ceiling. Since 2025, a Medicare drug plan caps what an enrollee pays out of pocket for covered medications at $2,000 a year, a figure that rises modestly with inflation, and the plan covers the rest once that cap is reached. A lower recognized price for semaglutide means a beneficiary reaches that ceiling more slowly, stretching the same out-of-pocket dollars across more of the year. Enrollees who still find the early-year bills heavy can spread them into level monthly installments through the Medicare Prescription Payment Plan instead of absorbing a large charge at a single pharmacy visit.
The savings extend past any single patient. Federal estimates tied to the round-two prices project roughly $12 billion in annual savings for the Medicare program and about $685 million in reduced out-of-pocket costs for enrollees once the prices take effect. Because semaglutide is used by a large and growing share of older Americans, the Ozempic cut carries a disproportionate weight inside those totals.
Timing matters for anyone counting on the lower figure. The negotiated price does not apply retroactively and does not take hold the moment it is announced. It becomes effective on January 1, 2027, which means a beneficiary filling Ozempic through the rest of 2026 is still paying under the old pricing structure. The relief is real but scheduled, and it arrives with the new plan year rather than immediately.
Why the fine print still decides the counter price
A negotiated price is not the same as a guaranteed copay, and that distinction is where confusion tends to start. The $274 figure fixes what Medicare pays, but each Part D plan still designs its own formulary tiers and cost-sharing rules on top of it. Two enrollees taking the identical drug can owe different amounts depending on which plan they chose and which phase of the benefit they are in when they fill the prescription.
Coverage placement is the other variable. A plan generally must cover a negotiated drug, but the tier it assigns and any utilization rules still shape the out-of-pocket total. That makes the 2027 plan-comparison season the moment to confirm how a specific plan treats semaglutide, rather than assuming the negotiated headline automatically becomes the checkout price.
Coverage also turns on why the drug is prescribed. Medicare’s drug benefit is barred by law from paying for medicines used solely for weight loss, so semaglutide is covered when prescribed for type 2 diabetes as Ozempic, while the same molecule marketed for obesity has faced far narrower Medicare coverage. That legal line means the negotiated diabetes price does not automatically translate into inexpensive weight-loss treatment for enrollees, a distinction easily lost in coverage that treats the drugs as interchangeable.
The broader significance, tracked closely by analysts at the health-policy organization KFF, is that Ozempic is one of 15 drugs in this negotiation round, and the program is designed to keep adding medicines in the years ahead. The $274 price is the most visible result so far, but it is one entry in a widening list. For a retiree, the takeaway is concrete: the drug that once carried a four-figure list price will be recognized by Medicare at roughly a quarter of that in 2027, and the leftover question is only how each plan chooses to pass the savings through.
This article was produced with AI assistance and reviewed against primary sources by The Money Overview editorial team.
More Financial Reading
